Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China.
National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
JAMA Netw Open. 2024 Aug 1;7(8):e2427266. doi: 10.1001/jamanetworkopen.2024.27266.
Despite posing a significant challenge to global tuberculosis (TB) elimination efforts, recurrent TB remains understudied due to the challenges of long-term observation.
To investigate the burden of recurrent TB using data from patients with pulmonary TB (PTB) in China.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included all bacteriologically confirmed or clinically diagnosed PTB cases reported to the Tuberculosis Information Management System with completed or successful treatment outcomes from January 1, 2005, to December 31, 2021. Data were analyzed from July 15, 2022, to October 28, 2023.
Newly diagnosed PTB was classified into primary, hematogenous disseminated, or secondary PTB.
The primary outcome was the annual recurrence rate, stratified by disease classification, over the 17-year observation period. The recurrence rate for year n was calculated by dividing the number of patients with recurrent TB in year n by observed person-years in year n. The secondary outcome was the annual proportion of recurrent TB among reported cases and associated risk factors.
Of 13 833 249 patients with TB reported to the Tuberculosis Information Management System, 10 482 271 with PTB met the inclusion criteria. Of these, 68.9% were male, 22.3% were 65 years or older, 89.6% were of Han ethnicity, and 68.4% were agricultural workers. A total of 413 936 patients experienced a recurrent TB episode after successful treatment, resulting in an overall recurrence rate of 0.47 (95% CI, 0.47-0.48) per 100 person-years. The recurrence rate for patients with primary PTB was 0.24 (95% CI, 0.22-0.26) per 100 person-years; for hematogenous disseminated PTB, 0.37 (95% CI, 0.36-0.38) per 100 person-years; and for secondary PTB, 0.48 (95% CI, 0.47-0.48) per 100 person-years. The cumulative proportion of recurrences within the first 2 years accounted for 48.9% of all recurrent cases. The proportion of recurrent cases among notified incident cases increased 1.9-fold from 4.7% in 2015 to 8.8% in 2021. Among other factors, ages 45 to 64 years (adjusted hazard ratio, 1.77 [95% CI, 1.65-1.89]) and having completed treatment (adjusted hazard ratio, 1.16 [95% CI, 1.14-1.18]) were identified as associated with recurrence.
In this retrospective cohort study, the PTB recurrence rate was substantially higher than the incidence, and the proportion of recurrent cases increased. Almost half of the recurrence occurred within the first 2 years, suggesting that routine posttreatment follow-up may represent an important strategy for accelerating TB elimination.
尽管复发性结核病对全球结核病(TB)消除工作构成重大挑战,但由于长期观察的挑战,复发性结核病的研究仍然不足。
利用中国肺结核(PTB)患者的数据来调查复发性结核病的负担。
设计、设置和参与者:本回顾性队列研究纳入了 2005 年 1 月 1 日至 2021 年 12 月 31 日期间结核病信息管理系统报告的所有经细菌学证实或临床诊断的 PTB 病例,且治疗结局完整或成功。数据分析于 2022 年 7 月 15 日至 2023 年 10 月 28 日进行。
新发 PTB 分为原发性、血源性播散性或继发性 PTB。
主要结局是在 17 年观察期内,按疾病分类的年度复发率。第 n 年的复发率通过将第 n 年复发的患者数量除以第 n 年的观察人年数来计算。次要结局是报告病例中复发性 TB 的年度比例及其相关危险因素。
在结核病信息管理系统报告的 13833249 例结核病患者中,有 10482271 例符合 PTB 纳入标准。其中,68.9%为男性,22.3%为 65 岁及以上,89.6%为汉族,68.4%为农业劳动者。共有 413936 例患者在成功治疗后经历了复发性结核病发作,总复发率为 0.47(95%CI,0.47-0.48)/100 人年。原发性 PTB 患者的复发率为 0.24(95%CI,0.22-0.26)/100 人年;血源性播散性 PTB 为 0.37(95%CI,0.36-0.38)/100 人年;继发性 PTB 为 0.48(95%CI,0.47-0.48)/100 人年。所有复发病例中,前 2 年内累计复发比例占 48.9%。在报告的新发病例中,复发病例的比例从 2015 年的 4.7%增加到 2021 年的 8.8%,增加了 1.9 倍。在其他因素中,45 岁至 64 岁(调整后的危险比,1.77[95%CI,1.65-1.89])和完成治疗(调整后的危险比,1.16[95%CI,1.14-1.18])被确定与复发相关。
在这项回顾性队列研究中,PTB 的复发率明显高于发病率,而复发病例的比例有所增加。近一半的复发发生在最初的 2 年内,这表明常规治疗后随访可能是加速结核病消除的重要策略。